Cargando…
Complementarity-determining region clustering may cause CAR-T cell dysfunction
Chimeric antigen receptor (CAR)-T cell therapy is rapidly advancing as cancer treatment, however, designing an optimal CAR remains challenging. A single-chain variable fragment (scFv) is generally used as CAR targeting moiety, wherein the complementarity-determining regions (CDRs) define its specifi...
Autores principales: | Sarén, Tina, Saronio, Giulia, Marti Torrell, Paula, Zhu, Xu, Thelander, Josefin, Andersson, Yasmin, Hofström, Camilla, Nestor, Marika, Dimberg, Anna, Persson, Helena, Ramachandran, Mohanraj, Yu, Di, Essand, Magnus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415375/ https://www.ncbi.nlm.nih.gov/pubmed/37563127 http://dx.doi.org/10.1038/s41467-023-40303-z |
Ejemplares similares
-
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
por: Hillerdal, Victoria, et al.
Publicado: (2014) -
Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer
por: Vaccaro, Alessandra, et al.
Publicado: (2023) -
CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers
por: Jin, Chuan, et al.
Publicado: (2022) -
Safe engineering of CAR T cells for adoptive cell therapy of cancer using long‐term episomal gene transfer
por: Jin, Chuan, et al.
Publicado: (2016) -
Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma
por: van de Walle, Tiarne, et al.
Publicado: (2021)